Humacyte Total Stockholder Equity vs Cash And Short Term Investments Analysis
| HUMA Stock | USD 4.49 0.11 2.51% |
Humacyte financial indicator trend analysis is much more than just examining Humacyte latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Humacyte is a good investment. Please check the relationship between Humacyte Total Stockholder Equity and its Cash And Short Term Investments accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Humacyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Humacyte Stock refer to our How to Trade Humacyte Stock guide.
Total Stockholder Equity vs Cash And Short Term Investments
Total Stockholder Equity vs Cash And Short Term Investments Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Humacyte Total Stockholder Equity account and Cash And Short Term Investments. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Humacyte's Total Stockholder Equity and Cash And Short Term Investments is 0.4. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Cash And Short Term Investments in the same time period over historical financial statements of Humacyte, assuming nothing else is changed. The correlation between historical values of Humacyte's Total Stockholder Equity and Cash And Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Humacyte are associated (or correlated) with its Cash And Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Short Term Investments has no effect on the direction of Total Stockholder Equity i.e., Humacyte's Total Stockholder Equity and Cash And Short Term Investments go up and down completely randomly.
Correlation Coefficient | 0.4 |
| Relationship Direction | Positive |
| Relationship Strength | Weak |
Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Cash And Short Term Investments
Short Term Investments is an account in the current assets section of Humacyte balance sheet. This account contains Humacyte investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Humacyte fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.Most indicators from Humacyte's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Humacyte current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Humacyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Humacyte Stock refer to our How to Trade Humacyte Stock guide.The current year's Enterprise Value is expected to grow to about 284.9 M, whereas Selling General Administrative is forecasted to decline to about 21.1 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 4.3M | 6.2M | 1.1M | 1.1M | Depreciation And Amortization | 8.3M | 8.3M | 7.7M | 8.7M |
Humacyte fundamental ratios Correlations
Click cells to compare fundamentals
Humacyte Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Humacyte is a strong investment it is important to analyze Humacyte's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Humacyte's future performance. For an informed investment choice regarding Humacyte Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Humacyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Humacyte Stock refer to our How to Trade Humacyte Stock guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Humacyte. If investors know Humacyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Humacyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.34) | Quarterly Revenue Growth (1.00) | Return On Assets (0.53) | Return On Equity (8.51) |
The market value of Humacyte is measured differently than its book value, which is the value of Humacyte that is recorded on the company's balance sheet. Investors also form their own opinion of Humacyte's value that differs from its market value or its book value, called intrinsic value, which is Humacyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Humacyte's market value can be influenced by many factors that don't directly affect Humacyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Humacyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Humacyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Humacyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.